Affordable Access

deepdyve-link
Publisher Website

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.

Authors
  • Stangelberger, Anton
  • Schally, Andrew V
  • Rick, Ferenc G
  • Varga, Jozsef L
  • Baker, Benjamin
  • Zarandi, Marta
  • Halmos, Gabor
Type
Published Article
Journal
The Prostate
Publisher
Wiley (John Wiley & Sons)
Publication Date
Apr 01, 2012
Volume
72
Issue
5
Pages
555–565
Identifiers
DOI: 10.1002/pros.21458
PMID: 21796649
Source
Medline
License
Unknown

Abstract

Our findings indicate that the anti-proliferative effects of GHRH antagonist MZ-J-7-138 and LHRH antagonist Cetrorelix on prostate cancers involve p53 and p21 signaling.

Report this publication

Statistics

Seen <100 times